Lupus Nephritis - Pipeline Review, H2 2016

Publication ID:
GMD0916062

Publication Date:
September 28, 2016

Pages:
142

Publisher:
Global Markets Direct

Region:
Global [1]

$2,000.00

Publication License Type *
○ Single User License (PDF), $2,000.00
○ Site License (PDF), $4,000.00
○ Global License (PDF), $6,000.00

Please choose the suitable license type from above. More details are at given under tab “Report License Types” below.

Description:
Lupus Nephritis - Pipeline Review, H2 2016
Summary


The report provides comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lupus Nephritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lupus Nephritis
- The report reviews pipeline therapeutics for Lupus Nephritis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Lupus Nephritis therapeutics and enlists all their major and minor projects
- The report assesses Lupus Nephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Lupus Nephritis
Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Lupus Nephritis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

**Table Of Contents:**

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Lupus Nephritis Overview 9
Therapeutics Development 10
Pipeline Products for Lupus Nephritis - Overview 10
Pipeline Products for Lupus Nephritis - Comparative Analysis 11
Lupus Nephritis - Therapeutics under Development by Companies 12
Lupus Nephritis - Therapeutics under Investigation by Universities/Institutes 14
Lupus Nephritis - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Lupus Nephritis - Products under Development by Companies 18
Lupus Nephritis - Products under Investigation by Universities/Institutes 20
Lupus Nephritis - Companies Involved in Therapeutics Development 21
AbbVie Inc 21
Asahi Kasei Pharma Corp. 22
Aug 15, 2016: Aurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIb AURA-LV Study in Lupus Nephritis 127
Jun 28, 2016: Aurinia Announces 24 Week Remission Rates from the First Seven Patients in its Open Label AURION Study in Lupus Nephritis (LN) 129
Jun 10, 2016: Alliance for Children Therapeutics Presents Dalazatide Data Demonstrating Positive Response in Lupus 130
May 23, 2016: KPI Therapeutics to Present Updated Dalazatide Study Data in Lupus 131
May 12, 2016: Aurinia Announces Presentations at the European Renal Association - European Dialysis and Transplant Association Meeting 131
May 09, 2016: Aurinia Initiates First Clinical Study of Voclosporin for Japan 132
Apr 20, 2016: Patient Dosing Initiated for OMS721 Phase 2 Program in Renal Diseases 133
Mar 29, 2016: Aurinia Announces Result from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis - Study to Continue as Planned 134
Mar 02, 2016: Aurina Receives FDA Fast Track Designation for Voclosporin for the Treatment of Lupus Nephritis 135
Feb 08, 2016: Aurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis 135
Feb 02, 2016: Deltanoid Pharmaceuticals Announces Appointment of Douglas Jermasek as Chief Executive Officer 136
Jan 19, 2016: Aurinia Announces Completion of Patient Enrollment in Its Phase 2B AURA-LV Study in Lupus Nephritis 137
Dec 03, 2015: Ocata’s Hemangio-derived Mesenchymal Cells Preserve Kidney Function and Extend Lifespan in Preclinical Model of Lupus Nephritis 138
Nov 24, 2015: Aurinia Pharmaceuticals Announces Outcome from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis - Study to Continue as Planned 139
Nov 10, 2015: Kineta, Seattle Children’s Research Institute Present New Data Demonstrating Positive, Predictive Responses to Dalazatide In Lupus 139
List of Tables

Number of Products under Development for Lupus Nephritis, H2 2016 10
Number of Products under Development for Lupus Nephritis - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Late Stage Development, H2 2016 15
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Development, H2 2016 17
Products under Development by Companies, H2 2016 18
Products under Development by Companies, H2 2016 (Contd..1) 19
Products under Investigation by Universities/Institutes, H2 2016 20
Lupus Nephritis - Pipeline by AbbVie Inc, H2 2016 21
Lupus Nephritis - Pipeline by Asahi Kasei Pharma Corp., H2 2016 22
Lupus Nephritis - Pipeline by Astellas Pharma Inc., H2 2016 23
Lupus Nephritis - Pipeline by Aurinia Pharmaceuticals Inc, H2 2016 24
Lupus Nephritis - Pipeline by Azano Pharmaceuticals Inc., H2 2016 25
Lupus Nephritis - Pipeline by Boehringer Ingelheim GmbH, H2 2016 26
Lupus Nephritis - Pipeline by Bristol-Myers Squibb Company, H2 2016 27
Lupus Nephritis - Pipeline by Deltanoid Pharmaceuticals Inc., H2 2016 28
Lupus Nephritis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 29
Lupus Nephritis - Pipeline by GlaxoSmithKline Plc, H2 2016 30
Lupus Nephritis - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 31
Lupus Nephritis - Pipeline by Invion Limited, H2 2016 32
Lupus Nephritis - Pipeline by KPI Therapeutics, Inc., H2 2016 33
Lupus Nephritis - Pipeline by MedImmune, LLC, H2 2016 34
Lupus Nephritis - Pipeline by Omeros Corporation, H2 2016 35
Lupus Nephritis - Pipeline by Ra Pharmaceuticals, Inc., H2 2016 36
Lupus Nephritis - Pipeline by Resolve Therapeutics, LLC, H2 2016 37
Lupus Nephritis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 38
Lupus Nephritis - Pipeline by TxCell SA, H2 2016 39
Assessment by Monotherapy Products, H2 2016 40
Number of Products by Stage and Target, H2 2016 42
Number of Products by Stage and Mechanism of Action, H2 2016 44
Number of Products by Stage and Route of Administration, H2 2016 46
Number of Products by Stage and Molecule Type, H2 2016 48
Lupus Nephritis - Dormant Projects, H2 2016 124
Lupus Nephritis - Dormant Projects (Contd..1), H2 2016 125
Lupus Nephritis - Discontinued Products, H2 2016 126

List of Figures
Number of Products under Development for Lupus Nephritis, H2 2016 10
Number of Products under Development for Lupus Nephritis - Comparative Analysis, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Comparative Analysis by Clinical Stage Development, H2 2016 16
Comparative Analysis by Early Stage Products, H2 2016 17
Assessment by Monotherapy Products, H2 2016 40
Number of Products by Top 10 Targets, H2 2016 41
Number of Products by Stage and Top 10 Targets, H2 2016 41
Number of Products by Top 10 Mechanism of Actions, H2 2016 43
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 43
Number of Products by Routes of Administration, H2 2016 45
Number of Products by Stage and Routes of Administration, H2 2016 45
Number of Products by Molecule Types, H2 2016 47
Number of Products by Stage and Molecule Types, H2 2016 47

Companies Mentioned:
AbbVie Inc
Asahi Kasei Pharma Corp.
Astellas Pharma Inc.
Aurinia Pharmaceuticals Inc
Azano Pharmaceuticals Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Deltanoid Pharmaceuticals Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
HanAll Biopharma Co., Ltd.
Invion Limited
KPI Therapeutics, Inc.
MedImmune, LLC
Omeros Corporation
Ra Pharmaceuticals, Inc.
Resolve Therapeutics, LLC
Takeda Pharmaceutical Company Limited
TxCell SA
License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.
Links

[1] https://www.drugpipeline.net/region/global